Ignite Creation Date:
2024-07-17 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06473610
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-19
Brief Title:
Residual Embolism Evaluated With Single Photon Emission Computed Tomography
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Organization:
Centre Hospitalier Universitaire de Saint Etienne
Study Overview
Official Title:
Residual Embolism Evaluated With Single Photon Emission Computed Tomography - The RESPECT Cohort
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RESPECT
Brief Summary:
Major progress achieved in diagnostic and therapeutic strategies has substantially improved the short-term prognosis of patients with pulmonary embolism PE These improvements have led to a shift from an acute to a chronic condition of venous thromboembolism justifying the recent development of Chronic Thrombo-embolic Disease CTED In most of the situations it is due to a residual pulmonary vascular obstruction RPVO which can be assessed by pulmonary scintigraphy
Detailed Description:
Planar ventilationperfusion VQ scintigraphy is the gold standard but for several months VQ single photon emission computed tomography SPECT is recommended in the guidelines
The aim of this study is to evaluate the performances of various SPECT protocols to quantified RPVO and compared to planar scintigraphy to evaluate the RPVO
The aim of this study is to evaluate the performances of various SPECT protocols to quantified RPVO and compared to planar scintigraphy to evaluate the RPVO
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2024-A00613-44 | OTHER | None | None |